Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses by Chiang, Chen-Yi et al.
Dengue-1 Envelope Protein Domain III along with PELC
and CpG Oligodeoxynucleotides Synergistically
Enhances Immune Responses
Chen-Yi Chiang
1., Ming-Hsi Huang
1., Chun-Hsiang Hsieh
1, Mei-Yu Chen
1, Hsueh-Hung Liu
1,
Jy-Ping Tsai
1, Yi-Shiuan Li
1, Ching-Yun Chang
1, Shih-Jen Liu
1,2, Pele Chong
1,2, Chih-Hsiang Leng
1,2*,
Hsin-Wei Chen
1,2*
1National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan, 2Graduate Institute of Immunology, China Medical
University, Taichung, Taiwan
Abstract
The major weaknesses of subunit vaccines are their low immunogenicity and poor efficacy. Adjuvants can help to overcome
some of these inherent defects with subunit vaccines. Here, we evaluated the efficacy of the newly developed water-in-oil-
in-water multiphase emulsion system, termed PELC, in potentiating the protective capacity of dengue-1 envelope protein
domain III. Unlike aluminum phosphate, dengue-1 envelope protein domain III formulated with PELC plus CpG
oligodeoxynucleotides induced neutralizing antibodies against dengue-1 virus and increased the splenocyte secretion of
IFN-c after in vitro re-stimulation. The induced antibodies contained both the IgG1 and IgG2a subclasses. A rapid
anamnestic neutralizing antibody response against a live dengue virus challenge was elicited at week 26 after the first
immunization. These results demonstrate that PELC plus CpG oligodeoxynucleotides broaden the dengue-1 envelope
protein domain III-specific immune responses. PELC plus CpG oligodeoxynucleotides is a promising adjuvant for
recombinant protein based vaccination against dengue virus.
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Introduction
Dengue is the most important mosquito-borne flavivirus disease.
People living in the tropical and subtropical areas are at risk of
dengue virus infection, and more than 50 million dengue infected
cases occur worldwide each year [1,2]. Vaccine inoculation is a
cost-effective way of combating the threat of infectious diseases. In
the past six decades, tremendous effort has been made to develop a
dengue vaccine [3–5]. However, despite these efforts, no licensed
dengue vaccines are currently available.
Many advanced biological technologies have been applied to
dengue vaccine development, and numbers of vaccine approaches
are currently in pre-clinical or clinical development. These
approaches include chimerization with other flaviviruses or the
deletion of portions of the genomes to obtain live attenuated
dengue vaccines, viral vector vaccines, DNA vaccines, and
recombinant subunit vaccines [3–5]. All of the approaches are
associated with different advantages and disadvantages. Among
these approaches, the recombinant subunit vaccine provides the
greatest degree of safety.
Dengue envelope protein domain III has been shown to be
involved in host receptor binding [6,7], and several neutralizing
epitopes have been identified within this domain [8–13]. These
characteristics of the envelope protein domain III indicate that it
wouldbeapromisingdenguevaccinecandidate[14].Severalsubunit
vaccines based on recombinant dengue envelope protein domain III
have been developed to protect against dengue viral infection [15–
23]. Formulating dengue subunit vaccine candidates with proper
adjuvants [15–17,21–23] or expressing vaccine candidates in a
lipoprotein [18–20] was necessary to enhance their immunogenicity.
These results indicate that one of the major weaknesses of subunit
vaccines is their low immunogenicity and that appropriate adjuvants
or delivery systems are required to overcome this weakness.
Adjuvants and delivery systems have noticeably improved over
the past several years. We previously developed a bioresorbable
diblock tri-component copolymer poly(ethylene glycol)-block-
poly(lactide-co-e- caprolactone) mixed with squalene and SpanH85
to produce homogeneous nano-particles (PELC). This water-in-
oil-in-water multiphase emulsion system can be utilized for vaccine
delivery [24–26]. In addition, we demonstrated that a formulation
of inactivated influenza virus and CpG oligodeoxynucleotides
(CpG) could enhance both the overall immune response and cross-
clade protective immunity [27]. These results indicate that PELC-
formulated vaccines has improved potential efficacy.
www.plosntds.org 1 May 2012 | Volume 6 | Issue 5 | e1645In this study, we evaluated the potential of aluminum
phosphate, CpG, PELC, and PELC plus CpG as adjuvants to
enhance the immunogenicity of recombinant dengue-1 envelope
protein domain III (D1ED III). We demonstrated that recombi-
nant D1ED III formulated with PELC plus CpG induced stronger
and broader immune responses than using other adjuvant
formulations. These results provide valuable information for
future clinical studies.
Materials and Methods
Ethics statement
Animal studies were carried out in strict accordance with the
recommendations from Taiwan’s Animal Protection Act. The
protocol was approved by the Animal Committee of the National
Health Research Institutes (Protocol No: NHRI-IACUC-098014)
and were performed according to their guidelines.
Cloning and expression of recombinant D1ED III
A consensus sequence for D1ED III from dengue-1 viruses was
obtained by aligning five amino acid sequences from different
isolates of the dengue-1 virus [21]. According to the amino acid
sequence of D1ED III, the DNA sequence of the D1ED III gene
was derived using codon usage of Escherichia coli and was fully
synthesized using the assembly PCR method [28]. The product of
the assembly PCR was then amplified by conventional PCR. To
generate an expressing plasmid for recombinant D1ED III, the
following primers were used: forward primer, 59-GGAATTCCA-
TATGaaaggcatgagctatgtgatgt -39 (Nde I site, underlined); reverse
primer, 59- CCGCTCGAGgctgctgccttttttaaa -39 (Xho I site,
underlined). The PCR product was cloned into the expression
vector pET-22b(+) (Novagen, Madison, WI), using Nde I and Xho
I sites to produce the pDen1E3 plasmid. As a result, the C-
terminus of the recombinant protein contained an additional
hexahistidine tag (HisTag). The Escherichia coli strain BL21 (DE3)
(Invitrogen, Carlsbad, CA) was transformed with the expression
plasmid pDen1E3 for protein expression. The transformed cells
were cultured at 37uC overnight, and protein expression was
induced by adding 1 mM isopropylthiogalactoside for 20 hours at
20uC.
Purification and characterization of recombinant D1ED III
The recombinant D1ED III was purified by disrupting the
harvested cells in a French Press (Constant Systems, Daventry,
UK) at 27 Kpsi in homogenization buffer (20 mM Tris (pH 8.0),
50 mM sucrose, 500 mM NaCl and 10% glycerol). The cell lysate
was clarified by centrifugation (80,0006 g for 40 min). The
majority of recombinant D1ED III was found in the soluble
fraction. The recombinant D1ED III was purified using immo-
bilized metal affinity chromatography (IMAC) columns. The
eluent from the IMAC column was then polished using an anion
exchange column (Q sepharose fast flow; GE) after dialysis against
Q buffer (20 mM Tris-Cl, 1 m MEDTA, pH 8.0). E membrane
(Pall, USA) was used to remove the endotoxin. The endotoxin
levels of the purified recombinant D1ED III were determined by
the Limulus amebocyte lysate assay (Associates of Cape Cod, Inc.
Cape Cod, MA), and the resulting endotoxin levels were found to
be below the detection limit of the kit (,3 EU/mg). The fractions
from each step were analyzed by SDS-PAGE gel stained with
Coomassie blue (Coomassie Brilliant Blue R-250) and were
immunoblotted with anti-HisTag antibodies.
The purified recombinant D1ED III was dialyzed against
5 mM ammonium bicarbonate, pH 8.5. Dialyzed samples were
mixed with trypsin (Promega Co., Madison, WI, USA) at a 50:1
ratio (wt/wt) in 25 mM ammonium bicarbonate, pH 8.5. The
reaction allowed to continue for 2 hours and stopped by adding
formic acid at a final concentration of 1.2%. The tryptic peptides
were analyzed by MALDI-TOF (Burker) mass spectrometry.
Adjuvant preparation
Murine CpG was synthesized by Invitrogen Taiwan Ltd and was
givenasa10 mg dose dissolvedinthesterilewaterorintheantigenic
media. The CpG sequence used was 59-TCCATGACGTTCCT-
GACGTT-39 with all phosphorothioate backbones. Aluminum
phosphate suspensionwas kindly providedby the Taiwan CDC and
given as a 300 mg dose in acidic media (pH 6). PELC is a squalene
W/O/W nanoemulsion stabilized by SpanH85 (sorbitan trioleate,
Sigma-Aldrich, Steinheim, Germany) and PEG-b-PLACL, the
latter consisting of 75 wt-% of hydrophilic bioabsorbable PEG
and 25 wt-% of lipophilic biodegradable PLACL with molecular
weight of 7,000 daltons as previously described [24–26]. Briefly,
120 mgofPEG-b-PLACL,0.8 mL ofphosphate buffersaline (PBS),
and 1.1 mL of oily solution consisting of squalene (Sigma-Aldrich,
Steinheim, Germany) and SpanH85 (85/15 v/v) were emulsified
using PolytronHPT 3100 homogenizer (Kinematica AG, Switzer-
land) at 6,000 rpm for 5 min. The emulsified PELC formulation
was stored at 4uC until use. PELC-formulated vaccine was
investigated by re-dispersing 0.2 mL of stock emulsion into
1.8 mL of aqueous solution and mixed with a test-tube rotator
(Labinco LD-79, Netherlands) at 5 rpm for at least 1 hour before
injection. Recombinant D1ED III and/or CpG were introduced in
the aqueous solution, respectively.
Virus
Dengue-1 (Hawaii) was used for this study. The virus was
propagated in Vero cells, and viral titers were determined by
focus-forming assays with BHK-21 cells.
Mouse experiments
Five BALB/c mice (6–8 weeks of age) were immunized
subcutaneously with recombinant D1ED III (10 mg per dose,
Author Summary
Dengue is a mosquito-borne disease. Infection of dengue
virus can cause clinical manifestations ranging from self-
limiting dengue fever to potentially life-threatening
dengue hemorrhagic fever or dengue shock syndrome.
In recent years, dengue has spread to most tropical and
subtropical areas, making it a global health concern.
Specific approaches for dengue therapy do not exist; the
development of a dengue vaccine would represent a
major advance in the control of the disease. Currently, no
licensed dengue vaccine is available. Subunit vaccines
provide a great safety strategy for developing dengue
vaccine. However, the major weaknesses of subunit
vaccines are low immunogenicity and poor efficacy. Here
we employed dengue-1 envelope protein domain III as a
model vaccine candidate and described a newly devel-
oped water-in-oil-in water multiphase emulsion system to
overcome the inherent defect of subunit vaccines. We
showed that emulsification of dengue-1 envelope protein
domain III and CpG oligodeoxynucleotides synergistically
broadened immune responses and potentiated the pro-
tective capacity of dengue-1 envelope protein domain III.
These results provide valuable information for develop-
ment of recombinant protein based vaccination against
dengue virus and future clinical studies.
Immunogenicity of Dengue-1 ED III
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two-week interval with the same regimen. To detect the
anamnestic response generated by immunization, immunized
mice were inoculated intraperitoneally with 3610
6 focus-forming
units (FFU) of live dengue-1 virus. Blood was collected from each
mouse at different time points, as indicated. Sera were prepared
and stored at 220uC until use.
ELISPOT assays
The numbers of IFN-c- and IL-4-producing cells were
determined using mouse IFN-c and IL-4 ELISPOT kits
(eBioscience), respectively. All of the assays were performed
according to the manufacturer’s instructions. Briefly, 96-well
plates with PVDF membranes (Millipore) were coated with
capture antibody and incubated at 4uC for 18 hours. The plates
were washed twice and blocked with RPMI medium supplement-
ed with fetal bovine serum (10%) for one hour to prevent
nonspecific binding in later steps. Splenocytes were seeded at a
concentration of 5610
5 cells/well and stimulated with D1ED III
(10 mg/mL) for 3 days at 37uC in a 5% CO2 humidified incubator.
After incubation, the cells were removed from the plates by
washing three times with 0.05% (w/v) Tween 20 in PBS. A
100 mL aliquot of biotinylated detection antibody was then added
to each well. The plates were incubated at 37uC for 2 hours. The
washing steps were repeated as above, and after a 45-minute
incubation at room temperature with the avidin-horseradish
peroxidase (HRP) complex reagent, the plates were washed three
times with 0.05% (w/v) Tween 20 in PBS and then three times
with PBS alone. A 100 mL aliquot of 3-amine-9-ethyl carbazole
(Sigma-Aldrich) staining solution was added to each well to
develop the spots. The reaction was stopped after one hour by
placing the plates under tap water. The spots were counted using
an ELISPOT reader (Cellular Technology Ltd.). The values
presented in the results are mean 6 standard deviation of each
group.
Antibody response measurement
The levels of anti-D1ED III IgG in the serum samples were
determined by titrating the samples. Sera were diluted using 3-fold
serial dilutions (starting at 1:33). Briefly, purified D1ED III was
coated on 96-well plates. In some experiments, supernatant
obtained from dengue-1 virus infected Vero cells was coated on
96-well plates (2610
4 ffu virus/well). Bound IgG was detected
with HRP-conjugated goat anti-mouse IgG Fc. After the addition
of 3, 39,5 ,5 9-tetramethylbenzidine (TMB), the absorbance was
measured with an ELISA reader at 450 nm. For measurement of
IgG1 and IgG2a anti-D1ED III subclass, biotin-conjugated rat
anti-mouse IgG1 and rat anti-mouse IgG2a were used as
detectors, and avidin-HRP was then added. Color was developed
as described above. ELISA end-point titers were defined as the
serum dilution that gave a 0.5 OD value. The serum dilution was
obtained from the titration curve by interpolation, unless the OD
value was less than 0.5 at the starting dilution (1:33).
Immunofluorescence assay
BHK-21 cells were infected with dengue-1 virus. Three days
after infection, the cells were fixed for 15 min in 3.7%
formaldehyde/PBS. After washing with PBS, the cells were
permeabilized with 0.1% Nonidet P40/PBS for 15 min and
blocked with 3% bovine serum albumin (BSA)/PBS for 30 min.
Viruses in the infected cells were detected by mouse pre-immune
and immune sera (from D1ED III-immunized mice). After
washing with PBS, antibody-labeled cells were detected using a
secondary antibody conjugated with fluorescein isothiocyanate
(FITC). Cellular DNA was labeled by Hoechst stains.
Focus reduction neutralization tests (FRNT)
Sera were diluted using 2-fold serial dilutions (starting at 1:8)
and the sera were heat inactivated prior to testing. A monolayer of
BHK-21 cells in 24-well plates was inoculated with dengue-1 virus
that had been pre-mixed at 4uC overnight with pre-immunization
or post-immunization sera to a final volume of 0.5 mL. The virus
titer prior to pre-mixing was about 20–40 FFU per well. Viral
adsorption was allowed to proceed for 3 hours at 37uC. An overlay
medium containing 2% fetal bovine serum and 0.8% methylcel-
lulose in DMEM was added at the conclusion of adsorption. The
infected monolayer was incubated at 37uC. After 72 hours of
infection, the overlay medium was removed from the wells, and
the BHK cells were washed with cold PBS. The cells were fixed for
15 min in 3.7% formaldehyde/PBS. After washing with PBS, the
cells were permeabilized with 0.1% Nonidet P40/PBS for 15 min
and blocked with 3% bovine serum albumin (BSA)/PBS for
30 min. Infected cells were detected by a monoclonal anti-dengue
antibody (American Type Culture Collection, No. HB-114). After
washing with PBS, antibody-labeled cells were detected using a
secondary antibody conjugated to HRP. The labeling was
visualized using TMB. The FFUs were counted, and the
neutralizing antibody titer FRNT50 (or FRNT80) was calculated
as the reciprocal of the highest dilution that produced a 50% (or
80%) reduction of FFU compared with control samples containing
the virus alone. For calculation purpose, the neutralizing antibody
titer was designated as 2
2 when neutralizing antibody titer was less
than 2
3.
Blocking of dengue virus infection to BHK-21 cells by
D1ED III
To test whether D1ED III blocks dengue virus infection of
BHK-21 cells, virus was pre-mixed with different amount D1ED
III or control BSA protein as indicated for 10 min at 4uC. Viral
adsorption was allowed to proceed for 3 hours at 37uC. The FFUs
were determined as described above.
Statistical analyses
The statistical analysis was conducted using GraphPad Prism
version 5.02 (GraphPad Software, Inc.). Data from D1ED III
blocking dengue-1 viral infection were processed by a two-tailed
Student’s t-test. Data from ELISPOT assay were analyzed by the
Mann-Whitney test. Data from ELISA and FRNT were
performed by the ANOVA Bonferroni post test. Differences with
a p value of less than 0.05 were considered statistically significant.
Results
Expression and purification of recombinant dengue-1
envelope protein domain III
The D1ED III amino acid sequence is a consensus sequence of
dengue virus type 1 aligned from selected target sequences
(Accession number: P27909, P27913, P17763, P33478 and
P27912) [21]. The DNA sequence of the D1ED III gene was
derived using codon usage with Escherichia coli and was fully
synthesized using the assembly PCR method. The PCR product
was cloned into the pET22b vector for recombinant D1ED III
expression. The recombinant protein contained an additional
HHHHHH sequence (HisTag) at the C-terminus and was
expressed under the control of the T7 promoter (Figure 1A).
The recombinant D1ED III was purified using an immobilized
Immunogenicity of Dengue-1 ED III
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exchange column (Figure 1B, lanes 1–4). Recombinant D1ED III
was detected with anti-HisTag antibodies (Figure 1B, lanes 5–8).
After the lipopolysaccharide (LPS) was removed (less than 3 EU/
mg), purified recombinant D1ED III was comparatively analyzed
for its immunogenicity and efficacy in animal models. Recombi-
nant D1ED III was also digested with trypsin to assess its peptide
mass fingerprinting. The molecular weight of recombinant D1ED
III is 12377. All major peaks in the spectrum at m/z 983.41,
1050.51, 1184.68, 1310.55, 1314.58, 1442.68, 1637.88, and
2559.29 cover over 80% of recombinant D1ED III. The results
confirmed that the major peaks in the mass spectra were derived
from recombinant D1ED III (Figure 1C).
Recombinant D1ED III can block dengue-1 viral infection
Dengue envelope protein domain III has been show to be
involved in cellular receptor binding [6,7]. We hypothesized that if
purified recombinant D1ED III exists in a suitable conformation,
then soluble D1ED III should interfere with dengue viral
infections. As shown in Figure 2, the ability of dengue-1 virus to
infect BHK-21 cells was inhibited in the presence of D1ED III in a
dosage-dependent manner. Greater than 80% reduction of focus
number was observed when D1ED III added to cells at a
concentration of 0.15 mg/mL. BSA did not inhibit dengue-1 focus
formation at concentrations as high as 1.5 mg/mL, which is 10-
fold higher than D1ED III. These results suggest that D1ED III
can block the cellular binding sites of the dengue-1 virus.
Figure 1. Expression and purification of recombinant D1ED III. (A) The DNA sequence of the D1ED III gene was derived using codon usage of
Escherichia coli and fully synthesized using the assembly PCR method. The PCR product was cloned into the pET22b vector for recombinant D1ED III
expression. The recombinant protein contained an additional HHHHHH sequence (HisTag) at the C-terminus and was expressed under the control of
the T7 promoter. (B)The recombinant D1ED III protein purification process was monitored using 17.5% reducing SDS-PAGE followed stained by
Coomassie Blue staining and immunoblotting using anti-HisTag antibodies. The recombinant D1ED III was expressed in Escherichia coli strain BL21
(DE3). Lane 1, recombinant D1ED III expression after IPTG induction; lane 2, protein expression in the absence of IPTG induction; lane 3, soluble
fraction of recombinant D1ED III; lane 4, purified recombinant D1ED III. Lanes 5–8 show immunoblotting to monitor the recombinant D1ED III
induction and purification processes, and the samples in these lanes are the same as those in lanes 1–4, respectively. The arrows indicate the
electrophoretic positions of recombinant D1ED III in the gels or blots. (C) Recombinant D1ED III was digested with trypsin to assess their peptide mass
fingerprinting. The results confirmed that the major peaks in the mass spectra were derived from recombinant D1ED III.
doi:10.1371/journal.pntd.0001645.g001
Immunogenicity of Dengue-1 ED III
www.plosntds.org 4 May 2012 | Volume 6 | Issue 5 | e1645Immunogenicity of purified D1ED III formulated with
different adjuvants
The purified recombinant D1ED III vaccine candidate was
formulated with different adjuvants and then tested for its ability to
induce both T- and B-cell immune responses in mice. Groups of
BALB/c mice were immunized with the different formulations two
times with a two-week interval between immunizations. Animals
immunized with PBS alone served as controls. One week after the
second immunization, splenocytes were harvested and examined
for IFN-c and IL-4 secretion in response to three days of D1ED III
stimulation. The ability of the different formulations to induce
cytokine secretion varied greatly, as shown in Figure 3. The
frequency of IFN-c spots per 10
6 splenocytes in mice immunized
with recombinant D1ED III alone was 4.964.4 (n=5) spots.
Splenocytes from mice immunized with recombinant D1ED III
formulated with aluminum phosphate (21.6617.4, n=9, p,0.05
compared to D1ED III alone), CpG (7.664.3, n=4, p.0.05
compared to D1ED III alone), and PELC (24.9614.3, n=4,
p.0.05 compared to D1ED III alone) showed modest increases in
IFN-c spots. Mice immunized with recombinant D1ED III
formulated with PELC plus CpG elicited the highest number of
IFN-c spots (85.9670.3, n=9, p,0.05 compared to D1ED III
alone, alum, or CpG) (Figure 3A). Although the formulation using
PELC plus CpG elicited fewer IL-4 spots than the aluminum
phosphate formulation (89.7648.6 vs. 140.7687.0), the difference
was not statistically significant (p=0.1903). Interestingly, the
PELC plus CpG formulation elicited more IL-4 spots than the
formulations using PELC (28.369.7, p,0.05) or CpG (25.1610.9,
p,0.05) alone (Figure 3B).
Next, we evaluated the IgG antibody responses following three
immunizations with two-week intervals between immunizations.
Serum samples were collected from the immunized mice at
different time points, as indicated in Figure 4A. Formulations of
recombinant D1ED III with PELC or PELC plus CpG were
highly immunogenic and generated stronger antibody responses
than the other formulation groups (p,0.05 by the ANOVA
Bonferroni post test). All of the antibody responses peaked between
week 4 and week 8 after the first immunization. Importantly,
substantial levels of anti-D1ED III IgG antibodies were detectable
for over 20 weeks after the initial priming. Sera collected from
different formulation groups at week 6 were analyzed for presence
of IgG1 (Figure 4B) and IgG2a (Figure 4C). Mice immunized with
the CpG formulation generated lower levels of IgG1 antibody than
mice that received the aluminum phosphate, PELC, and PELC
plus CpG formulations (p,0.05 by the ANOVA Bonferroni post
test). The PELC and PELC plus CpG groups had significant levels
of IgG1 in comparison with the other groups (p,0.05 by the
ANOVA Bonferroni post test). The combination of PELC and
CpG induced the highest levels of IgG2a (p,0.05 by the ANOVA
Bonferroni post test). As shown in Figure 4D, the ratios of IgG2a
to IgG1 in mice receiving PELC plus CpG formulation were
higher than those observed in mice receiving the antigen alone,
aluminum phosphate, or PELC formulations (p,0.05 by the
ANOVA Bonferroni post test). These results indicate that
combination of CpG and PELC could improve the IgG2a
response.
Figure 2. Soluble D1ED III inhibits dengue-1 infection to BHK
21 cells. Dengue-1 virus was pre-mixed with different amount of D1ED
III or control bovine serum albumin (BSA) protein as indicated for
10 min at 4uC. Viral adsorption on a monolayer of BHK-21 cells in 24-
well plates proceeded for 3 hours at 37uC. The FFUs were determined 3
days after the viral infection. The results are pooled from two
independent experiments. The p values were calculated using an
unpaired two-tailed Student’s t-test.
doi:10.1371/journal.pntd.0001645.g002
Figure 3. Cytokine profiles induced by D1ED III formulated
with various adjuvants. BALB/c mice were immunized subcutane-
ously twice with 10 mg of D1ED III in PBS or in combination with Alum,
CpG, PELC, or PELC plus CpG at a two-week interval. Mice immunized
with PBS alone (without D1ED III) served as controls. Seven days after
the final immunization, splenocytes were stimulated with D1ED III
(10 mg/mL) for 72 h. The frequencies of (A) IFN-c- and (B) IL-4-secreting
cells in the spleens were determined using mouse IFN-c and IL-4
ELISPOT kits, respectively. The results are pooled from two independent
experiments. The p values were calculated using the two-tailed Mann-
Whitney test.
* p,0.05 compared to control.
# p,0.05 compared to
PBS.
1 p,0.05 compared to Alum.
{ p,0.05 compared to CpG.
{ p,0.05
compared to PELC.
doi:10.1371/journal.pntd.0001645.g003
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neutralize the infectivity of the dengue-1 virus
As the preceding experiments showed that the various
formulations of recombinant D1ED III used could elicit consid-
erable antibody responses, we wondered whether these antibodies
would recognize the dengue-1 virus. To address this, we employed
indirect immunofluorescence staining to evaluate antibody spec-
ificity in the sera of mice immunized with the various formulations
of recombinant D1ED III. As shown in Figure 5A, naı ¨ve serum
did not produce immunofluorescent reactivity with dengue-1 virus
infected cells. Weak immunofluorescence signals were observed in
sera obtained from mice immunized with recombinant D1ED III
alone or formulated with CpG. In contrast, strong immunofluo-
rescence signals were observed in sera obtained from mice
immunized with the aluminum phosphate, PELC, and PLEC
plus CpG formulations. These results suggest that the antibodies
induced by recombinant D1ED III can react with dengue-1 virus.
To further examine whether D1ED III raised antibodies can
recognize native dengue-1 virus, ELISA was performed by using
dengue-1 virus coated 96-well plates. In comparison with naı ¨ve
serum, sera obtained from mice immunized with D1ED III alone
or with various adjuvants produced significantly higher OD values
(p,0.05 by the ANOVA Bonferroni post test). These results
demonstrated that antibodies induced by D1ED III can recognize
native dengue-1 virus (Figure 5B).
The major objective of this study was to explore whether any of
the formulations of recombinant D1ED III could induce
neutralizing antibodies responses. To evaluate the dengue-1 virus
neutralizing ability of the antibodies induced by vaccination,
antisera from the mouse immunized with the various formulations
were collected, and the neutralizing antibody titers were assessed
by focus reduction neutralization tests (FRNT). As shown in
Table 1, mice immunized with recombinant D1ED III formulated
without adjuvant or with aluminum phosphate, CpG or PELC
could not generate significant neutralizing antibody responses
(neutralizing antibody titers FRNT50,2
3). In contrast, mice
received PELC plus CpG formulation elicited detectable neutral-
izing antibody titers (FRNT50=2
4.6).
Figure 4. Humoral immune responses induced by D1ED III formulated with various adjuvants. Groups of BALB/c mice (n=5) were
immunized subcutaneously with 10 mg of D1ED III three times either in PBS or in combination with Alum, CpG, PELC, or PELC plus CpG at a two-week
interval. (A) Sera were collected from mice at the indicated time points after the first immunization. IgG antibodies against D1ED III were evaluated
using ELISA. Pre-immune sera (week 0) were collected and used as basal levels for comparison. (B) IgG1 and (C) IgG2a antibodies of serum samples
obtained from 6 weeks post-prime immunization against D1ED III were evaluated by ELISA. (D) The ratios of IgG2a/IgG1 are shown. ELISA end-point
titers were defined as the serum dilution that gave a 0.5 OD value. The serum dilution was obtained from the titration curve by interpolation, unless
the OD value was less 0.5 at the starting dilution (1:33). The results are expressed as the mean 6 SD. Statistical significance was determined by the
ANOVA Bonferroni post test at the same time point.
* p,0.05 compared to PBS.
# p,0.05 compared to Alum.
1 p,0.05 compared to CpG.
{ p,0.05
compared to PELC.
doi:10.1371/journal.pntd.0001645.g004
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anamnestic neutralizing antibody responses
As the formulation of recombinant D1ED III with PELC plus
CpG could elicit the strongest cellular and humoral immune
responses and neutralizing antibody responses of all the formula-
tions we tested, we further evaluated the protective efficacy of the
D1ED III with PELC plus CpG formulation. Groups of BALB/c
mice were immunized with various amounts (3, 10, or 30 mg/dose)
of D1ED III three times at two-week intervals. The animals were
then injected intraperitoneally with dengue-1 virus (3610
6 FFU/
mouse) 26 weeks after the first immunization. Serum samples were
collected from the mice at the indicated time points, and the
neutralizing capacity against dengue-1 virus was examined. As
shown in Table 2, no significant neutralizing activity was detected
in the sera obtained from naı ¨ve mice before and after viral
infection (neutralizing antibody titers ,2
3). Mice immunized with
3, 10, or 30 mg of D1ED III produced neutralizing antibody
responses at week 6 after initial priming. The neutralizing
antibody titers waned at week 24 after the first immunization.
At 6 days post-viral challenge, the neutralizing antibody titers
FRNT50 were 2
3.8,2
4.4, and 2
4.2 in mice received vaccination with
3, 10, or 30 mg/dose, respectively. These results provide tangible
evidence that an efficient anamnestic neutralizing antibody
response was induced in mice immunized with recombinant
D1ED III formulated with PELC plus CpG.
Discussion
Adjuvants containing aluminum (alum) are currently the most
widely used adjuvants in human vaccines. However, formulations
of dengue subunit vaccines using alum were unable to induce
complete protection against dengue virus infection [15,29–32]. In
Figure 5. The capability of D1ED III induced antibodies to recognize and neutralize dengue-1 virus. Mice were immunized with D1ED III
(10 mg/dose) formulated with the indicated adjuvants three times at two-week intervals. (A) Serum samples were collected 8 weeks after the first
immunization. BHK-21 cells were infected with dengue-1 virus at multiplicity of infection 0.3 for 3 days. Virus-infected cells were fixed and probed
with sera drawn from before (naı ¨ve) or after immunization with D1ED III. Cellular DNA was visualized by Hoechst stains (left panels). Dengue-1 virus
infected cells were shown as FITC stains (middle panels). The right panels show the images of merging Hoechst and FITC stains. Magnification for
each image is 2006. (B) Serum samples were collected 8 weeks after the first immunization. ELISA was performed by using dengue-1 virus as coating
antigen. Naı ¨ve sera were used as basal levels for comparison. The results are presented as mean 6 SD from triplicate wells.
doi:10.1371/journal.pntd.0001645.g005
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www.plosntds.org 7 May 2012 | Volume 6 | Issue 5 | e1645the present study, we prepared D1ED III as a dengue subunit
vaccine candidate (Figure 1). The purified D1ED III formed in the
proper conformation, which could occupy the cellular binding sites
to reduce dengue virus infection (Figure 2). We also found that
D1ED III formulated with aluminum phosphate could not induce
a significant neutralizing antibody response (Table 1). Altogether,
Table 1. Neutralizing antibody titers in mice immunized with D1ED III formulated with various adjuvants
1.
Adjuvants FRNT50 FRNT80
Mouse 1 2 3 4 5 12345
PBS ,8 ,8 ,88 8 ,8 ,8 ,8 ,8 ,8
Alum ,8 ,88 8 1 6 ,8 ,8 ,8 ,8 ,8
CpG ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
PELC ,8 ,88 8 8 ,8 ,8 ,8 ,8 ,8
PELC+CpG 8 16 16 64 64
*#1{2 ,8 ,8 ,8 ,88
1Mice were immunized with D1ED III (10 mg/dose) formulated with the indicated adjuvants three times at two-week intervals. Serum samples (n=5) were collected on 2
weeks after the last immunization. The dengue-1 virus neutralizing capacity was determined by FRNT. The neutralizing antibody titer was calculated as the reciprocal of
the highest dilution that resulted in a 50% or 80% reduction of FFU compared to control samples containing the virus alone.
2Statistical analysis was performed by the ANOVA Bonferroni post test.
*p,0.05 compared to PBS.
#p,0.05 compared to Alum.
1p,0.05 compared to CpG.
{p,0.05 compared to PELC.
doi:10.1371/journal.pntd.0001645.t001
Table 2. Neutralizing antibody titers in mice immunized with D1ED III formulated with PELC plus CpG before and after viral
challenge
1.
Time Groups FRNT50 FRNT80
Mouse 1 234512345
6 weeks post prime Naı ¨ve ,8 ,8 ,88 8 ,8 ,8 ,8 ,8 ,8
3 mg 8 8 1 61 63 2,8 ,8 888
10 mg 8 16 32 32 32
*2 ,8 ,8 881 6
*
30 mg 8 8 1 63 26 4
* 8881 6 3 2
*#1
24 weeks post prime naı ¨ve ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
3 mg ,8 ,8 ,88 1 6 ,8 ,8 ,8 ,8 ,8
10 mg ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
30 mg ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
6 days post challenge naı ¨ve ,8 ,8 ,88 8 ,8 ,8 ,8 ,8 ,8
3 mg 8 8 1 61 63 2
* ,8 ,8 ,8 ,88
10 mg 8 16 32 32 32
* ,8 ,8 ,88 8
30 mg 8 8 1 63 26 4
* ,8 8888
*
14 days post challenge naı ¨ve ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8 ,8
3 mg ,8 ,8 ,88 3 2 ,8 ,8 ,8 ,8 ,8
10 mg ,8 8883 2 ,8 ,8 ,8 ,8 ,8
30 mg ,8 8 16 32 32
* ,8 ,8 ,8 ,8 ,8
22 days post challenge naı ¨ve ,8 ,8 ,8 ,88 ,8 ,8 ,8 ,8 ,8
3 mg ,8 ,8 ,8 ,88 ,8 ,8 ,8 ,8 ,8
10 mg ,8 ,8 883 2 ,8 ,8 ,8 ,8 ,8
30 mg ,8 1 63 23 23 2
*# ,8 ,8 ,8 ,88
1Groups of BALB/c mice (n=5) were immunized three times subcutaneously with 3, 10, or 30 mg of D1ED III formulated with PELC plus CpG at two-week intervals. Naı ¨ve
mice without immunization served as controls. All animals were inoculated intraperitoneally with 3610
6 FFU of live dengue-1 virus at week 26 post-priming. Sera were
collected at different time points as indicated. The sera’s ability to neutralize dengue-1 virus was determined by FRNT. The neutralizing antibody titer was calculated as
the reciprocal of the highest dilution that resulted in a 50% or 80% reduction of FFU compared to control samples containing the virus alone.
2Statistical analysis was performed by the ANOVA Bonferroni post test at the same time point.
*p,0.05 compared to naive.
#p,0.05 compared to 3 mg.
1p,0.05 compared to 10 mg.
doi:10.1371/journal.pntd.0001645.t002
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subunit vaccines. In the present study, we evaluated the suitability
of PELC-based adjuvants to potentiate the neutralizing antibody
capacity of the D1ED III in the mouse model.
All the mice immunized with D1ED III formulated without or
with various adjuvants could induce a D1ED III-specific antibody
response (Figure 4A). We also noticed that antibodies elicited in all
of the immunized groups could recognize dengue-1 virus infected
cells (Figure 5A and 5B). However, none of antibodies exhibited a
significant neutralizing capacity aside from the antibodies obtained
from PELC plus CpG immunized mice (Table 1). In addition,
sizeable anamnestic neutralizing antibody responses were observed
in mice immunized with D1ED III formulated with PELC plus
CpG (Table 2). These results indicate that PELC plus CpG is a
promising potential adjuvant for dengue subunit vaccines.
The antibody-dependent enhancement (ADE) of flavivirus
infection can be inhibited by complement protein C1q. The
inhibition effect is IgG subclass-specific. ADE induced by an
IgG2a monoclonal antibody but not by an epitope-matched IgG1
monoclonal antibody could be inhibited by purified C1q [33]. Our
results show that different adjuvant formulations can alter the ratio
of IgG1/IgG2a (Figure 4D). Interestingly, a significant level of
IgG2a was induced in mice immunized with the PELC plus CpG
formulation (Figure 4C). These results indicate that D1ED III
formulated with PELC plus CpG induces an IgG2a-biased
response that may possibly reduce the risk of ADE when sufficient
serum C1q levels are present.
Alum predominantly induces a Th2 polarized response [34–37]
featuring IL-4 production. Consistent with these findings, D1ED
III formulated with aluminum phosphate induced higher IL-4
production than any of the other adjuvant formulations that we
tested (Figure 3B). Interestingly, the PELC plus CpG formulation
induced both vigorous IFN-c and IL-4 responses (Figure 3). IFN-c
has been shown to play an important role in antiviral activity
against dengue virus [38,39]. The induction of strong IFN-c
responses by the PELC plus CpG formulation will be greatly
advantageous in protecting hosts against dengue virus.
There are some of limitations for in vivo protection studies due
to the lack of a relevant mouse model of dengue infection. In the
present study, we utilized dengue-1 virus as an antigenic challenge
model to evaluate memory neutralizing antibody responses. Our
results show that the low neutralizing antibody titers were induced
and diminished at 24 weeks after immunization of D1ED III
formulated with PELC plus CpG (Table 2). Interestingly, quick
anamnestic neutralizing antibody responses were evoked when
stimulated with dengue-1 virus in mice immunized with D1ED III
formulated with PELC plus CpG but not naı ¨ve mice (Table 2).
These results suggest that memory neutralizing antibody responses
were induced in mice immunized with D1ED III formulated with
PELC plus CpG.
Our findings show that the PELC plus CpG formulation
improves both the intensity and quality of the immune responses
against D1ED III. Moreover, the immune responses induced by
the PELC plus CpG formulation are beneficial to host protection
against dengue viral infection. In conclusion, PELC plus CpG is
an attractive adjuvant for dengue subunit vaccines based on
recombinant envelope protein domain III. Future work should
expand to test the suitability of PELC plus CpG formulations in
non-human primate studies.
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